Escitalopram in the treatment of social anxiety disorder

Background Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice. Aims To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder. Method Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10–20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score. Results The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P < 0.0 1). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment. Conclusions Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.

[1]  C. Allgulander,et al.  Paroxetine in social anxiety disorder: a randomized placebo‐controlled study , 1999, Acta psychiatrica Scandinavica.

[2]  J. Pine,et al.  Comorbidity and social phobia: clinical and epidemiological issues , 1996 .

[3]  A. Norheim,et al.  A randomised , double-blind, placebo-controlled study , 2001 .

[4]  D. Stein,et al.  Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. , 2001, The Journal of clinical psychiatry.

[5]  R. Kessler,et al.  Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity , 1999, Psychological Medicine.

[6]  A. Pelissolo,et al.  Why take social anxiety disorder seriously? , 2000, Depression and anxiety.

[7]  D. Sheehan,et al.  The Anxiety Disease , 1984 .

[8]  H. Westenberg,et al.  Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. , 1998, The Journal of clinical psychiatry.

[9]  F. Schneier.  Paroxetine in social phobia/social anxiety disorder , 2000 .

[10]  J. Davidson,et al.  Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. , 1999, The American journal of psychiatry.

[11]  D. Stein,et al.  Paroxetine in social phobia/social anxiety disorder , 1999, British Journal of Psychiatry.

[12]  S. Kasper.  Social phobia: the nature of the disorder. , 1998, Journal of affective disorders.

[13]  J. Lépine,et al.  Comorbidity and social phobia: clinical and epidemiological issues , 1996, International clinical psychopharmacology.

[14]  M. Stein,et al.  A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. , 2002, The Journal of clinical psychiatry.

[15]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[16]  A. V. van Balkom,et al.  The placebo response in social phobia , 2001, Journal of psychopharmacology.

[17]  R. Bowen,et al.  Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. , 2001, The American journal of psychiatry.

[18]  S. Montgomery.  Implications of the severity of social phobia. , 1998, Journal of affective disorders.

[19]  J. Angst,et al.  Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.

[20]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[21]  M. Versiani.  A Review of 19 Double-Blind Placebo-Controlled Studies in Social Anxiety Disorder (Social Phobia) , 2000, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[22]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.